PF-01367338
- Product Name
- PF-01367338
- CAS No.
- 459868-92-9
- Chemical Name
- PF-01367338
- Synonyms
- CS-47;Rubraca;AG14699;AG-014699;PF-01367338;Rucaparib(AG-01);Rucaparib D4 HCl;AG014699 phosphate;AG 014699 phosphate;AG-014699 phosphate
- CBNumber
- CB82515928
- Molecular Formula
- C19H21FN3O5P
- Formula Weight
- 421.37
- MOL File
- 459868-92-9.mol
PF-01367338 Property
- Melting point:
- >173°C (dec.)
- storage temp.
- Sealed in dry,Room Temperature
- solubility
- Soluble in DMSO (up to 25 mg/ml).
- form
- Yellow solid.
- color
- Yellow
- Stability:
- Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months.
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Warning
- Hazard statements
-
H226Flammable liquid and vapour
H315Causes skin irritation
H319Causes serious eye irritation
- Precautionary statements
-
P210Keep away from heat/sparks/open flames/hot surfaces. — No smoking.
P233Keep container tightly closed.
P240Ground/bond container and receiving equipment.
P241Use explosion-proof electrical/ventilating/lighting/…/equipment.
P242Use only non-sparking tools.
P243Take precautionary measures against static discharge.
P264Wash hands thoroughly after handling.
P264Wash skin thouroughly after handling.
P280Wear protective gloves/protective clothing/eye protection/face protection.
P303+P361+P353IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.
P332+P313IF SKIN irritation occurs: Get medical advice/attention.
P337+P313IF eye irritation persists: Get medical advice/attention.
P370+P378In case of fire: Use … for extinction.
P403+P235Store in a well-ventilated place. Keep cool.
P501Dispose of contents/container to..…
N-Bromosuccinimide Price
- Product number
- 11570
- Product name
- Rucaparib (phosphate)
- Purity
- ≥98%
- Packaging
- 1mg
- Price
- $32
- Updated
- 2024/03/01
- Product number
- 11570
- Product name
- Rucaparib (phosphate)
- Purity
- ≥98%
- Packaging
- 5mg
- Price
- $139
- Updated
- 2024/03/01
- Product number
- 11570
- Product name
- Rucaparib (phosphate)
- Purity
- ≥98%
- Packaging
- 10mg
- Price
- $243
- Updated
- 2024/03/01
- Product number
- A425500
- Product name
- AG14699
- Packaging
- 5mg
- Price
- $90
- Updated
- 2021/12/16
- Product number
- A425500
- Product name
- AG14699
- Packaging
- 10mg
- Price
- $140
- Updated
- 2021/12/16
PF-01367338 Chemical Properties,Usage,Production
Description
Rucaparib phosphate (459868-92-9) is a potent (Ki<5 nM) PARP1 inhibitor.1?Cytotoxic to human cancer cells or xenograft tumors with mutated or epigenetically silenced BRCA1/2.2?Demonstrates antiproliferative effects in 26 out of 39 ovarian cancer cell lines.3?Synergizes with other anticancer agents such as topotecan, carboplatin, doxorubicin, paclitaxel,3 and temozolomide.4?Ameliorates the cardiotoxicity of doxorubicin.5?Recently approved for human use by the FDA.
Uses
PARP inhibitor oncolytic
in vivo
Rucaparib (AG014699) phosphate and AG14584 significantly increase Temozolomide toxicity. Rucaparib (1 mg/kg) phosphate significantly increases Temozolomide-induced body weight loss. Rucaparib (0.1 mg/kg) phosphate results in a 50% increase in the temozolomide-induced tumor growth delay[1].
Rucaparib (10 mg/kg for i.p. or 50, 150 mg/kg for p.o.; daily for 5 days per week for 6 weeks) phosphate significantly inhibits the growth of the tumor, and there is one complete tumor regression and two persistent partial regressions[2].
Rucaparib (150 mg/kg; p.o.; once per week for 6 weeks or three times per week for 6 weeks) phosphate has greatest antitumor effect with three complete regressions[2].
Rucaparib phosphate enhances the antitumor activity of temozolomide and indicates complete and sustained tumor regression in NB1691 and SHSY5Y xenografts[6].
| Animal Model: | Female athymic nude mice, implanted SW620 colorectal tumor cells (1 × 107 cells per animal) s.c.[1] |
| Dosage: | 0.1 mg/kg in combination with Temozolomide (p.o., 200 mg/kg), 0.05, 0.15, and 0.5 mg/kg in combination with Temozolomide (p.o., 68 mg/kg) or 10 mg/kg |
| Administration: | IP, single dose for 0.1 mg/kg and 10 mg/kg, five daily doses for 0-0.5 mg/kg |
| Result: | Significantly increased Temozolomide toxicity, showed outstanding chemosensitization potency and caused enhancement of Temozolomide-induced tumor growth delay |
| Animal Model: | CD-1 nude mice bearing established Capan-1 xenografts[2] |
| Dosage: | 10 mg/kg or 50, 100 and 150?mg/kg |
| Administration: | IP for 10 mg/kg; PO for 50, 100 and 150?mg/kg, single dose (Pharmacokinetics) |
| Result: | Parent drug was detectable in the plasma only at 30?min after 10?mg/kg i.p and up to 4?h for 50–150?mg/kg p.o.. Was still detectable in most mice receiving oral rucaparib at 3 days. Does not easily cross the plasma membrane. |
| Animal Model: | CD-1 nude mice bearing established Capan-1 xenografts[2] |
| Dosage: | 10?mg/kg i.p. daily for 5 days per week for 6 weeks, 50 or 150?mg/kg p.o. daily × five weekly × six, 150?mg/kg p.o. once per week for 6 weeks or three times per week for 6 weeks, or 150?mg/kg p.o. daily for five days every 3 weeks |
| Administration: | IP or PO |
| Result: | 10?mg/kg i.p. significantly inhibited the growth of the tumor, daily oral administration at 150?mg/kg had an equivalent effect on tumor growth to 10?mg/kg i.p.. The schedule with the greatest antitumor effect was oral administration of 150?mg/kg on a once weekly schedule with three complete regressions. |
| Animal Model: | CD-1 nude mice, NB1691 and SHSY5Y xenografts[6] |
| Dosage: | 1 mg/kg |
| Administration: | IP, daily for 5 d in combination with Temozolomide (orally daily ×5 at a dose of 68 mg/kg) |
| Result: | Enhanced the antitumor activity of Temozolomide and indicated complete and sustained tumor regression. |
IC 50
PARP-1: 1.4 nM (Ki); PARP-2; PARP-3
References
[1] HUW D THOMAS. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial.[J]. Molecular Cancer Therapeutics, 2007, 6 3: 945-956. DOI:10.1158/1535-7163.mct-06-0552
[2] YVETTE DREW. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.[J]. JNCI Journal of the National Cancer Institute, 2011, 103 4: 334-346. DOI:10.1093/jnci/djq509
[3] MAIKE IHNEN. Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer.[J]. Molecular Cancer Therapeutics, 2013, 12 6: 1002-1015. DOI:10.1158/1535-7163.mct-12-0813
[4] RUTH PLUMMER. A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation.[J]. Cancer Chemotherapy and Pharmacology, 2013, 71 5: 1191-1199. DOI:10.1007/s00280-013-2113-1
[5] MAJID ALI. The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice.[J]. Molecular Cancer Therapeutics, 2011, 10 12: 2320-2329. DOI:10.1158/1535-7163.mct-11-0356
PF-01367338 Preparation Products And Raw materials
Raw materials
Preparation Products
PF-01367338 Suppliers
- Tel
- --
- Fax
- --
- info@axonmedchem.com
- Country
- The Netherlands
- ProdList
- 477
- Advantage
- 30
View Lastest Price from PF-01367338 manufacturers
- Product
- Rucaparib 459868-92-9
- Price
- US $0.00-0.00/KG
- Min. Order
- 1KG
- Purity
- 99%
- Supply Ability
- 500000kg
- Release date
- 2023-04-06
- Product
- Rucaparib phosphate;PF01367338 phosphate 459868-92-9
- Price
- US $0.00-0.00/kg
- Min. Order
- 1kg
- Purity
- 98%
- Supply Ability
- 1Ton
- Release date
- 2022-09-30
- Product
- ;Rucaparib 459868-92-9
- Price
- US $206.30/g
- Min. Order
- 1g
- Purity
- 99%
- Supply Ability
- 1000G
- Release date
- 2021-06-08